Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

March 12, 2024

NASDAQ US Health Care Biotechnology earnings 32 min

Earnings Call Speaker Segments

Melissa Jarel

executive
#1

Thanks, operator, and good afternoon to all of you. We appreciate you being on this Heron Therapeutics call today as we go over the financial results the company posted for the fourth quarter, which closed on December 31, 2023. Joining me from Heron right now are Craig Collard, our Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President, Chief Development Officer; and Kevin Warner, Senior Vice President, Medical Affairs, Strategy, and Engagement. If you're on the conference call, slides are being provided through webcast, and after today's call wraps up, you can also find them on the investor relations page of our website. Before we get started, allow me to briefly remind everyone that forward-looking statements will be made by the company during this conference call. Please be aware that anything said that isn't a statement of historical fact counts as a forward-looking statement; that covers comments regarding the company's projections, expectations, plans, beliefs, and future performance, and all of these are forward-looking statements for purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Such statements rest on judgment and analysis as of the date of this conference call, and they face numerous important risks and uncertainties that might cause actual results to differ materially from those described in the forward-looking statement. The risks and uncertainties tied to the forward-looking statements made in this conference call and webcast are laid out in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Other than as required by law, Heron takes on no obligation to update these forward-looking statements to reflect future events or actual outcomes and has no intention of doing so. With that said, I'd now like to hand the call over to Craig Collard, Chief Executive Officer of Heron.

Craig Collard

executive
#2

Good afternoon, everyone, and thank you for joining us for Heron Therapeutics' fourth quarter 2023 earnings call. We're glad today to bring you up to speed on what we accomplished during 2023, how our finances look, where things stand with our development programs, the CrossLink training, and a bit of a look at the strategic direction for our products. When I came aboard as CEO of Heron Therapeutics in April of 2023, we moved aggressively to turn this business around. The first steps involved cutting headcount and expenses while bringing the right leadership team onboard. We carried out a thorough overhaul of how we handle our finances, which has boosted both efficiency and accountability throughout the company. This slide shows you just how many meaningful milestones we hit in 2023, leaving us in a strong position for 2024 and the years ahead. Our operational expenses went from $182 million in 2022 down to $135 million in 2023, and for 2024, operating expenses ought to land somewhere between $108 million and $116 million. Alongside that effort, we've focused on lifting our gross margin. In the past, this company's gross margins sat around 50%. But thanks to improved inventory management and renegotiated terms with our manufacturers, we've brought COGS down and pushed gross margins above 70%. Looking forward, we expect gross margins to keep climbing into the mid-70s range. Early in 2023, we wrapped up a capital raise, and that gives us sufficient cash to reach profitability by late 2024. We ended 2023 holding more than $80 million in cash and cash equivalents, which, once again, means we have the cash needed to hit profitability in Q4 of 2024. Further down the list, we got the Vial Access Needle, or VAN, project going again, as well as the prefilled syringe. Both efforts are coming along well, and we expect VAN approval by the end of this year, with prefilled syringe approval anticipated in 2026. Each of these will deliver meaningful enhancements to ZYNRELEF, our product indicated for post-operative surgical pain. Our oncology franchise keeps exceeding expectations, and I'm delighted to share that total net revenues reached $107.9 million, beating our full year 2023 guidance. We're also quite pleased with how ZYNRELEF did in Q4 of 2023. For the first time ever, we surpassed $5 million in net revenue for the quarter, and that happened even as the business was undergoing substantial change. Finally, in January 2024, we signed the CrossLink agreement and secured our label expansion for ZYNRELEF. Those two developments ought to meaningfully affect ZYNRELEF revenues as we progress through 2024 and beyond. Now, let's turn to product performance. The oncology business keeps surpassing what we had projected, as CINVANTI posted $94.9 million in net revenues for the year while SUSTOL reached $13 million; overall we're quite happy with the oncology franchise, and we expect these medicines to keep delivering the same steadiness they've shown in prior years. When it comes to where most of our product expansion will originate going forward, that's the acute franchise. We were delighted that ZYNRELEF achieved a quarterly net revenue record of $5.6 million, marking the very first occasion this product has exceeded $5 million in a single quarter. Acute care net revenues totaled $19.1 million for the year, and that figure encompassed $1.4 million in APONVIE net revenues. As we head into 2024, our view is that both ZYNRELEF and APONVIE hold strong positions. Thanks to the CrossLink partnership, an expanded label, along with rising morale, a better sales message and improved targeting, we're confident this will be an excellent year for the two products. Turning to the CrossLink partnership, the agreement was inked on January 7, and things truly launched in early February. Our training efforts started with face-to-face sessions for the CrossLink executive team, and those went very well. Through March and into early April we'll keep that effort going, resulting in more than 150 salespeople trained and ready. Once this first cohort finishes training, we'll keep expanding into additional regions of the country. Looking at this slide gives you a clearer picture of how our footprint will appear once CrossLink is fully implemented, and keep in mind this adds 650 more reps nationwide who will be completely trained. By the close of 2024, we expect the whole group to be fully trained and operational. We also think 2024 will show an impact from having this many representatives in place. That said, I want to keep expectations in check, since clearly some time will pass before everything is really running on all cylinders. My belief is that the real inflection for ZYNRELEF arrives as we enter 2025, following the VAN launch and with all the new reps fully trained, though we definitely have good momentum, and we expect CrossLink reps to make a difference in 2024. We've been exploring doing more at the ASC level, since we've worked to concentrate more of our efforts in the orthopedic space. Once the CrossLink partnership was signed, it became clearer and clearer that CrossLink holds a substantial footprint there, and that our product mix aligns with the ASC's strategy, which is to move these patients out of surgery and into rehab as fast as possible. Our perioperative one-two punch of APONVIE plus ZYNRELEF will prove hugely advantageous to our prospective partners at the ASC level. At this point I'll hand things over to Kevin Warner, the most recent addition to our team, who serves as Senior VP of Medical Affairs, Strategy and Engagement. With Kevin on board, we address a key requirement — direct, practical familiarity with what we offer at the level of the clinician — and he will play a major role shaping our ASC strategy going forward. Kevin, over to you.

Kevin Warner

executive
#3

Thanks, Craig. I'm genuinely excited to join the Heron Therapeutics team and to take on a role helping steer the commercial portfolio for acute care and oncology care products. As a pharmacist, my experience spans over 15 years in clinical pharmacy, with a focus on perioperative care. Beyond that, I've spent more than 10 years in drug development, discovery, and clinical trials, including time as Director of Pharmaceutical Sciences at Osteal Therapeutics. Serving as Heron's Senior Vice President of Medical Affairs, Strategy, and Engagement, I'll be tasked with supporting the accurate exchange of medical information between our organization and providers, so that patients are able to receive the best possible care. Forming strategic alliances and cooperating with physicians so that the products from Heron become part of standard medical practice, exactly as the clinical literature specifies. I look forward to joining our Heron colleagues in expanding the indications, availability, uptake, and published evidence for what we already sell and for what is coming next. My remarks today will concentrate on the acute care side of our business, because I have been lucky enough to build substantial hands-on familiarity with ZYNRELEF and APONVIE, witnessing directly how they help our patients and health systems. The Enhanced Recovery After Surgery guidelines rest on evidence and are essential both to how patients fare and to keeping a health system financially sound. So the key goals behind Enhanced Recovery After Surgery, or ERAS, are twofold: bringing down pain after an operation and cutting back on how many opioids patients need, plus getting a handle on nausea and vomiting that show up post-surgery. Both of those problems — pain afterward and the nausea and vomiting — sit near the very top of what worries patients and the clinicians treating them. That's where ZYNRELEF and APONVIE come in; in our view, they're the best available options in their class, offering long-acting solutions for exactly these problems. When we make ZYNRELEF and APONVIE the foundation of our ERAS protocols, our belief is that this could lift patient satisfaction overall, improve how patients do clinically, and raise their day-to-day quality of life. And from the standpoint of the institution, as we get behind ERAS, these two products — ZYNRELEF and APONVIE — can also have a positive impact on the finances of our hospitals. At present, CMS pays for each of these two products on its own in the hospital, the outpatient setting, and ambulatory surgical centers. On top of that, many commercial insurers are providing coverage for ZYNRELEF that sits outside the surgical bundle. Making our Enhanced Recovery After Surgery protocols work better, together with reimbursement kept separate from the surgical bundle, matters greatly both to the financial health of our health system and to how our patients fare clinically. I want to turn to APONVIE, which is aprepitant injectable emulsion, and talk about the unmet need that still exists as well as how little awareness there is. Because of when it occurs and the different stages of care in which patients can run into it, postoperative nausea and vomiting often goes unnoticed or is not recognized enough. Patients rank postoperative nausea and vomiting as the number one most undesirable postop complication. It also brings clinical risk factors that can result in longer length of stay, readmissions, and surgical complications. In high-risk patients, postoperative nausea and vomiting rates can climb as high as 80%. Under the present guidance, for patients who have risk factors—placing them in the moderate-to-high-risk category—three or four agents are advised. Within the United States, more than 65 million diagnostic and surgical procedures are carried out, and among those patients, 50% face moderate to high risk for postoperative nausea and vomiting. Aprepitant is available on the market today both as an oral formulation and as a prodrug infusion, fosaprepitant. With the oral version, onset of action is delayed by roughly 1 to 5 hours. Fosaprepitant calls for compounding plus an infusion lasting 20 to 30 minutes, after which the prodrug undergoes systemic conversion into its active form. As a result, these options have not seen broad uptake in the perioperative setting, even though a large-scale meta-analysis covering nearly 100,000 patients ranked aprepitant as the number 1 most effective antiemetic. Beyond efficacy, aprepitant offers an excellent safety profile and does not carry the typical side effects associated with our commonly used antiemetic therapies, including QT prolongation, sedation, anticholinergic effects, or extrapyramidal side effects. That safety profile matters greatly when multiple agents are being combined for our moderate and high-risk patients. CINVANTI can be given as a 30-second IV push and achieves rapid occupancy of the target receptor, which opens the door to wider use of aprepitant in the acute perioperative window by the clinicians most inclined to prescribe it, chiefly anesthesiologists. With APONVIE, the safety and efficacy data provide a long-acting option lasting 48 hours against postoperative nausea and vomiting, one of the most serious complications we see after surgery; we anticipate the revised guidance for preventing postoperative nausea and vomiting, due out in 2024, and believe it will bolster education and awareness regarding the difference APONVIE can make; as for ZYNRELEF, our efforts will center on expanding how many providers know about it and the related effects on patients. When it comes to ZYNRELEF's clinical trials, the results make the case on their own: it's the sole FDA-approved extended-release anesthetic, and the first, with demonstrated ability to lower both pain and opioid use. What I'd like to do now is walk through several key growth catalysts — some already in motion, others set to be implemented during this year. Let's start with the major label expansion ZYNRELEF received, which the FDA cleared on January 23, 2024. Under that expansion, the product is indicated for adults, via infiltration, to deliver post-surgical analgesia lasting as long as 72 hours following soft tissue and/or orthopedic procedures — foot and ankle among them, plus other procedures where articular cartilage isn't directly exposed. Effectively, that move doubled the count of meaningful indicated procedures. From my perspective as a clinician, if I'm looking at procedures where ZYNRELEF is indicated and makes sense to use, I'd say it applies to basically any procedure where a provider would normally send the patient home with an opioid prescription. For postoperative analgesia, they ought to be thinking about ZYNRELEF as the base layer, so that opioid requirements can be reduced or removed altogether, which helps limit acute pain, lowers the chance that chronic pain develops, and aids clinical recovery. Formulary substitution stands to be strongly affected by the label expansion as well. Quite a few formularies have been reluctant to bring it on because the indications were limited, and that means they have to keep multiple agents on the formulary, which drives budget consequences. With ZYNRELEF's label now covering a broader range of uses, competing products that market themselves as long-acting but never proved they outperform standard-of-care anesthetics no longer need to stay on formularies. That opens the door for ZYNRELEF to serve as the foundational long-acting option, combined with cheaper generic anesthetics to handle the acute phase. Beyond that, third-party evidence continues to come in, and what it shows lines up with what we saw in our clinical trials — meaningful impact on postoperative pain, opioid consumption, length of stay, and functional outcomes. The opioid crisis still dominates headlines, and in 2020 it drained an estimated $1.5 trillion from the U.S. health system while claiming numerous patient lives. Our key accrediting bodies and government agencies are watching this closely and stepping in. Opioid stewardship measurements are now part of what The Joint Commission requires for accreditation. Beginning in 2025, the No Pain Act is going to reimburse non-opioid options in outpatient surgery that have demonstrated an ability to cut down on or remove the need for opioids. Add to that the $53 billion in opioid settlements currently going out to states — those funds are earmarked for awareness, prevention, and treatment efforts around the opioid epidemic. Awareness and uptake of ZYNRELEF stand to be shaped significantly by all of this. From where I sit, the CrossLink partnership Craig talked about earlier will be among the biggest drivers. Adding those extra team members in the field, if you will, is going to be critical for getting ZYNRELEF rolled out effectively as the backbone of multimodal analgesia everywhere in the country, so that the way postoperative pain and opioid requirements are approached can be transformed across the entire surgical landscape. At this point, I'd like to turn things over to Dr. Bill Forbes.

Bill Forbes

executive
#4

Thanks, Kevin. We're definitely glad to have you on board with us. For ZYNRELEF, the chance to develop it further was seen as having 3 stages. Label expansion came first, and that's now been achieved. Then comes a change to the device itself — the vial access needle, or VAN. Last of all is the prefilled syringe, or PSS. As for the VAN, it's built to make things more efficient and easier to prepare, and it does that in 2 ways. First, the VAN replaces how the device currently goes to market, where a vented vial spike, or VVS, is included — the VAN takes its place. With the VAN, the drug product can be drawn into the syringe faster and more easily, and that syringe is what the physician uses to instill it into the patient. The VAN was made specifically for this, and in testing it has beaten other vented vial spikes on the market today. Second, by enclosing the ZYNRELEF vial inside the VAN's sterile shroud, the VAN enables an even more secure presentation of the product into the sterile field in the surgical room; that means operating room staff get a more efficient process for preparing the product for the physician to use; we expect VAN approval in Q4 of this year. Naturally, the PSS is the ultimate answer for making ZYNRELEF easy to use, and we anticipate PSS approval in Q4 of 2026. With this product presentation, the whole tray is sterilized and ready to use right away. A new container closure system and the sterilization process itself are the challenges for this program. When this becomes available, every barrier to preparation will be gone. With that, I'll hand things over now to Ira Duarte. Ira?

Ira Duarte

executive
#5

Appreciate that, Bill. Since Craig has already covered how our products did in his remarks, I'll just add a handful of other points about what we observed in Q4 2023 and how things have gone so far this year. Gross profit on products was $24.3 million for the fourth quarter, and $61.9 million for the twelve months ending December 31, 2023 — which works out to 71% and 49% of net revenue, respectively. Those yearly margins were hurt by write-offs of ZYNRELEF inventory taken during the year. Going forward, we aren't anticipating any meaningful ZYNRELEF write-offs. SG&A for the three and twelve months ended December 31, 2023, was $23.6 million and $116.7 million, respectively, compared with $26.7 million and $119.9 million in the same period of 2022. R&D expenses were $10.9 million and $55.9 million for the three and twelve months ended December 31, 2023, versus $11.1 million and $107.5 million in the comparable period of 2022. That reduced spending largely reflected lower costs associated with ZYNRELEF, as manufacturing scaled up and validation work along with raw material qualifications finished during 2022. Beyond that, personnel and related costs fell overall thanks to the reductions in force implemented in June 2022 and June 2023. We believe we can continue cutting costs in this area ahead as we keep realizing efficiencies. The net loss was $10.7 million in Q4 2023, and $19.9 million in the comparable period of 2022. As for the total year-to-date net loss, 2023 shows a net loss of $110.6 million, versus $182 million in the comparable period of 2022. I'd like to give a bit more visibility now into our total operational spend and cash burn for 2023. In early June we started implementing our corporate restructuring plan, which included multiple cost-saving measures, among them a reduction in force and a company-wide cutback in overall spend. Today we have much better visibility into our operational spend and can see a clear route to profitability. Moving across that slide from left to right, you'll see our total operational spend for 2023 came in at about $172 million, which fell to $155 million after we excluded reorganization charges of $18 million. After subtracting expenses for non-cash stock compensation not tied to severance, plus depreciation and amortization of $27 million, our cash OpEx spend for the year was $128 million; that compares with $177 million of cash OpEx spend for 2022. Keep in mind that we launched our company-wide reduction midway through 2023, and as we said on our previous earnings call, we expect our operational run rate ahead, excluding stock compensation and depreciation and amortization, to come in between $108 million-$160 million, while cash burn will decline each quarter as our spend has stabilized and revenues continue to grow each quarter. Turning to what we're projecting for 2024: the numbers we shared before still stand — revenue between $138 million and $158 million, with gross margins in the 60%-70% band. If you take out stock-based compensation, depreciation, and amortization, our operating expenses should come in around $108 million to $116 million. For EBITDA, once again leaving out stock comp, the result ought to be somewhere between a loss of $22 million and income of $3 million. I'll repeat that we expect to hit positive EBITDA in Q4 2024, and with that in mind — plus our strong balance sheet and the operating plan currently in place — we see no reason to go raise additional capital. That figure reflects an $8 million improvement, or 68%. With that, we're ready to take your questions.

Serge Belanger

analyst
#6

Am I coming through okay? Alright, understood. Understood. So I have a couple of inquiries regarding ZYNRELEF. First off, it has now been 6 or 7 weeks since the label expansion happened. I'm just wondering whether you've noticed any effect on demand or usage following that? And then second, perhaps you could explain what the No Pain Act signifies for ZYNRELEF. To be specific, what type of coverage exists at present, and how do you expect that to shift once we turn the calendar over to January 2025, at which point the No Pain Act goes into force? Thank you.

Craig Collard

executive
#7

Alright, sure. Yeah, I'd say — again, just from what we're hearing anecdotally — once the label expansion came through, there was obviously a great deal of enthusiasm. And when we head into centers where we've already established some business, going deeper into those accounts is definitely simpler, so we're seeing a bit of that. In fact, on the very first day after the label expansion, I believe I watched our initial on-label spine surgery. I was there in the OR in Asheville, North Carolina. So we're definitely getting some of that benefit. That said, I think when you pair it with CrossLink — we had a meeting at AAOS out in San Francisco, where we spent time with CrossLink and had physicians stopping by the booth and all of that, plus just the enthusiasm surrounding it — but I don't believe you'll necessarily witness a dramatic effect just yet, though we are definitely observing some effect. Still, I think, again, as time goes on, as I mentioned during my comments, I think with CrossLink, with the label expansion, and the VAN launch later this year, I think this truly starts gaining traction late in the year, moving into 2025, when we genuinely begin to see an inflection point; but we're definitely seeing some positive momentum. As for the No Pain Act, I'll hand it over to Kevin Warner, who can offer a bit more detail on that. Yeah. Hey, Serge, appreciate the question. So the No Pain Act is going to matter a great deal across several dimensions; what the No Pain Act does is deliver reimbursement in the hospital outpatient procedure department and the ambulatory surgical centers, for products demonstrated to lower the need for opioids; so where ZYNRELEF is concerned, we're already covered in both the HOPD and ASC through 2025 for Q1. The No Pain Act will run through 2027, so it will basically lock in that reimbursement for our facilities through 2027, and CMS has talked about a longer timeframe beyond that, potentially stretching all the way to 2030; so we're eager to work with our legislatures on this and keep securing reimbursement for our patients to make sure it's covered; but that will help guarantee adoption and pull-through for many institutions.

Serge Belanger

analyst
#8

Thank you.

Craig Collard

executive
#9

You're welcome.

Carl Byrnes

analyst
#10

I appreciate you taking the question, and congrats on both the results and the progress you've made. Given that 2025 is genuinely positioned as the ramp year for ZYNRELEF and APONVIE, how are you viewing... I realize you've already addressed some of this. In what way do you expect the CrossLink collaboration alongside the label expansion to carry over into ZYNRELEF sales during 2024? My recollection is that earlier guidance referenced acute care products growing 50% year-over-year. Are you at ease with that figure, or do you suspect it might end up looking too cautious? Thanks.

Craig Collard

executive
#11

Yes, once more, part of why we provided that range was that we couldn't be certain precisely when or in what manner this might gain traction; however, as you mentioned, with the broader label and what I can share regarding the CrossLink partnership — I mean, occasionally you enter one of these arrangements where everything appears to click perfectly in terms of the people involved and simply how the pieces fit together, and that's genuinely how we feel. The individuals at CrossLink have been outstanding. They clearly bring relationships that differ from those we might presently hold with certain surgeons and others. So thus far, that has been everything we hoped for. One thing that caught us off guard during the initial training session — I attended that one together with our team, and we conducted it in person — and once more, the reception was extremely positive; the executive team from CrossLink was present, and after that, just last week we held another in-person training with some of the sales staff over there, and we'll keep doing more of those; consequently, as I noted, within roughly the coming 30 days, we ought to have approximately 150 reps who will be essentially fully deployed and active. So once again, we will definitely observe some effect. I'm merely attempting to moderate expectations somewhat, because until we're truly fully operational and have done this for a period and trained additional regions across the country, I don't believe it will genuinely accelerate and inflect before next year. That said, positive developments are occurring right now, and we're happy. Up to this point, everything is proceeding according to plan.

Carl Byrnes

analyst
#12

Great. Thanks. And then just one more thing to ask about. It appears, and you brought this up once more, that there's a sizable chance in the ASC segment, especially for cross-selling ZYNRELEF as well as APONVIE through your sales team and via the CrossLink collaboration. Could you — would you mind expanding a bit on what you're thinking regarding the size of that potential? Thanks.

Craig Collard

executive
#13

Yeah. Well, of course, the market is heading in that direction. And once more, we've attempted to... I don't like saying we oversimplify, but we've genuinely attempted to head where we believed we'd succeed the most right now and to niche this product somewhat, which has brought us into orthopedics, and from there we will definitely grow. But that truly happens alongside the direction that space is taking with ASC. So when we examine our business, we believe a genuine chance exists, as that space grows, for us to genuinely be a real partner in that area. Because, once more, if you consider what an ASC aims for, it's getting these patients out fast, getting them to rehab. The worst thing you'd want is any patient who has, you know, any sort of nausea tied to the surgery returning to the hospital. And that's where a PONV can step in and matter, so, you know, for those patients at higher risk. So with our sort of perioperative one-two punch, we genuinely feel these two products are positioned ideally for precisely what the ASC is attempting to accomplish. And so, once more, with CrossLink already having, you know, some presence in that area, we believe that will be incredibly helpful in, you know, opening certain doors for us there and, and genuinely attempting to proceed along that path.

Carl Byrnes

analyst
#14

Great. Thanks, and congratulations again.

Craig Collard

executive
#15

Thanks, Carl.

Analyst

analyst
#16

Hello, I'm Claire, calling in on behalf of Kelly. Nice work on the impressive headway. I only have one brief thing about the expense cuts. I was curious whether you intend to push your cost-cutting initiative even further during 2024? In other words, ought we to anticipate that R&D plus SG&A will keep declining across 2024 and 2025? Also, when do you figure your operating costs are going to settle into something more steady? Thanks so much.

Craig Collard

executive
#17

Thank you, Claire. I'm grateful for that. Well, take a look — that band we provided, spanning $108 million-$116 million, I mean, once more, we would really like to land at the bottom of it; it's just that, once more, given that we've implemented a number of these adjustments, we're attempting to, you know, presently work out how that might shake out over this year, and we've allowed ourselves a small amount of leeway; however, my sense is you won't witness meaningful expense cuts beyond this point. My feeling is we've reached roughly a point where you can more or less count on things moving ahead. Still, once more, we're fairly at ease sitting inside that band.

Kelly Shi

analyst
#18

Got it. Thank you.

Craig Collard

executive
#19

Okay, thank you.

Craig Collard

executive
#20

I simply want to express gratitude to each of you for being on today's call, and we genuinely anticipate talking with all of you again in the next quarter. Thanks.

Operator

operator
#21

This concludes today's call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.